Trials / Active Not Recruiting
Active Not RecruitingNCT02711553
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 309 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramucirumab | Administered IV |
| DRUG | Merestinib | Administered orally |
| DRUG | Cisplatin | Administered IV |
| DRUG | Gemcitabine | Administered IV |
| DRUG | Placebo Oral | Administered orally |
| DRUG | Placebo IV | Administered IV |
Timeline
- Start date
- 2016-05-19
- Primary completion
- 2018-02-16
- Completion
- 2026-12-01
- First posted
- 2016-03-17
- Last updated
- 2025-08-03
- Results posted
- 2021-02-26
Locations
82 sites across 18 countries: United States, Argentina, Australia, Austria, Belgium, Czechia, Denmark, France, Germany, Hungary, Mexico, Russia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02711553. Inclusion in this directory is not an endorsement.